The Debate Is Over: This Cancer Stock Is Winning the GIST Race
In the last decade alone, scientists have made notable progress understanding cancer progression and developing targeted treatments that significantly improve outcomes. One of the best examples is gastrointestinal stromal tumors (GIST).
As recently as the late 1990s, doctors knew relatively little about the solid tumors, which meant GIST was often misdiagnosed as other cancers. Today, there are a handful of approved drugs targeting specific genetic mutations common in GIST. That's led to a footrace between Blueprint Medicines (NASDAQ: BPMC) and Deciphera Pharmaceuticals (NASDAQ: DCPH) to develop next-generation checkpoint inhibitors for the rare cancer.
While Wall Street had anointed Blueprint Medicines as the front-runner in the GIST race for the last several years, it's now clear that a drug from Deciphera Pharmaceuticals will provide the most benefit to patients. Here's the latest breakdown of the competitive landscape and what investors need to watch for these two healthcare stocks.
Source Fool.com
